68 results
8-K
EX-2.1
CHRS
Coherus BioSciences, Inc.
27 Jun 24
Coherus BioSciences Announces Divestiture of YUSIMRY (adalimumab-aqvh) in a $40 Million Upfront All Cash Transaction
8:52am
of the Business in any material respect, (e) Encumbrances arising out of conditional sale, title retention, consignment or similar arrangements … , the collection, recording, organization, structuring, retrieval,, de-identification, re-identification, sharing, combination of, use, compilation, retention
8-K/A
EX-10.2
CHRS
Coherus BioSciences, Inc.
21 May 24
Financial Statements and Exhibits
5:14pm
with the acquisition of properties, assets or businesses; (e) all indebtedness of such Person created or arising under any conditional sale or other title retention
8-K/A
EX-10.1
CHRS
Coherus BioSciences, Inc.
21 May 24
Financial Statements and Exhibits
5:14pm
in the Territory) from any unauthorized or unlawful access, acquisition, use, disclosure, transmission, retention, processing, loss, destruction … claims, in writing, related to, any loss, theft, unauthorized access to, or unauthorized acquisition, modification, disclosure, retention, processing
8-K
EX-2.1
f2e18g2ooq032 8iamb
22 Jan 24
Coherus Announces Agreement to Divest Ophthalmology Franchise to Sandoz in Conference Call Information
8:01am
424B3
z4yn7xsh34v0ii4u84p
26 Jul 23
Prospectus supplement
4:59pm
S-4/A
s93ka
24 Jul 23
Registration of securities issued in business combination transactions (amended)
4:42pm
S-4
5imacj t60fzcj5akdz
7 Jul 23
Registration of securities issued in business combination transactions
5:03pm
425
l6h304s
16 Jun 23
Business combination disclosure
5:17pm
425
15puutn
16 Jun 23
Business combination disclosure
5:16pm
425
h8kbag1 f7h
16 Jun 23
Business combination disclosure
5:14pm